Kailera Therapeutics, Inc. ( KLRA )

Other

Common Stock

10,276,820

-^{footnote F1}

Apr 20, 2026

Open-market purchase

Common Stock

500,000

$16.00

$8.00M

Apr 20, 2026

Other

Series A Preferred Stock

8,250,000

-^{footnote F1}

Apr 20, 2026

BAIN CAPITAL INVESTORS LLC

Other

Series B Preferred Stock

2,026,820

-^{footnote F1}

Footnote F1 (price): Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-1 basis and had no expiration date.

Apr 20, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. - 10% Owner

Other

Common Stock

9,477,719

-^{footnote F2}

Apr 20, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. - 10% Owner

Other

Common Stock

2,034,133

-^{footnote F2}

Apr 20, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. - 10% Owner

Other

Series A-2 convertible preferred stock

4,968,789

$0.00

Apr 20, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. - 10% Owner

Other

Series A-2 convertible non-voting preferred stock

708,814

$0.00

Footnote F2 (price): The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the… Full note on SEC EDGAR

Apr 20, 2026

Other

Common Stock

17,857,143

-^{footnote F1}

Apr 20, 2026

BAIN CAPITAL INVESTORS LLC

Open-market purchase

Common Stock

8,398,438

$16.00

$134.38M

Apr 20, 2026

BAIN CAPITAL INVESTORS LLC

Other

Series B Preferred Stock

17,857,143

$0.00

Footnote F1 (price): Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.

Apr 20, 2026

Other

Common Stock

16,875,000

-^{footnote F1}

Apr 20, 2026

Other

Common Stock

4,145,768

-^{footnote F2}

Apr 20, 2026

Open-market purchase

Common Stock

1,562,500

$16.00

$25.00M

Apr 20, 2026

Other

Series A-1 Preferred Stock

16,875,000

$0.00

Apr 20, 2026

Other

Series B Preferred Stock

4,145,768

$0.00

Apr 16, 2026

Grant or award

Stock Option (right to buy)

38,300

$0.00

Footnote F1 (price): Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.
Footnote F2 (price): Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.

Apr 20, 2026

Other

Common Stock

16,875,000

-^{footnote F1}

Apr 20, 2026

Other

Common Stock

4,145,768

-^{footnote F2}

Apr 20, 2026

Open-market purchase

Common Stock

1,562,500

$16.00

$25.00M

Apr 20, 2026

Other

Series A-1 Preferred Stock

16,875,000

$0.00

Apr 20, 2026

Other

Series B Preferred Stock

4,145,768

$0.00

Footnote F1 (price): Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.
Footnote F2 (price): Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.

Apr 20, 2026

Other

Common Stock

17,857,143

-^{footnote F1}

Apr 20, 2026

Open-market purchase

Common Stock

8,398,438

$16.00

$134.38M

Apr 20, 2026

Other

Series B Preferred Stock

17,857,143

$0.00

Apr 16, 2026